By Professor Michael Leonard Friedlander

Book Chapters

Berek JS; Renz M; Friedlander ML; Bast RC, 2022, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 23, http://dx.doi.org/10.1002/9781119000822.hfcm105.pub2

Berek JS; Renz M; Friedlander ML; Bast RC, 2022, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 18, http://dx.doi.org/10.1002/9781119000822.hfcm106.pub2

Christie EL; Freimund AE; Fereday S; Alsop K; Hoang T; Pishas K; Au-Yeung G; Friedlander M; Bowtell DD, 2020, 'The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer', in Overcoming Ovarian Cancer Chemoresistance, pp. 43 - 53, http://dx.doi.org/10.1016/B978-0-12-819840-7.00013-3

Amant F; Hensley M; Pautier P; Friedlander M; Sagae S; Fujiwara K; Berton Rigaud D; Lorusso D; Ray-Coquard I, 2020, 'Management of Rare Uterine Malignant Tumors', in Management of Endometrial Cancer, Springer International Publishing, pp. 277 - 312, http://dx.doi.org/10.1007/978-3-319-64513-1_19

Berek JS; Friedlander ML; Bast RC, 2017, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 27, http://dx.doi.org/10.1002/9781119000822.hfcm105

Berek JS; Friedlander ML; Bast RC, 2017, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 17, http://dx.doi.org/10.1002/9781119000822.hfcm106

Friedlander ML; Markman M, 2014, 'Chemotherapy', in Berek and Hacker S Gynecologic Oncology Sixth Edition, pp. 58 - 84

Berek JS; Friedlander ML; Hacker NF, 2014, 'Epithelial ovarian, fallopian tube, and peritoneal cancer', in Berek and Hacker S Gynecologic Oncology Sixth Edition, pp. 464 - 529

Berek JS; Friedlander ML; Hacker NF, 2014, 'Germ cell and nonepithelial ovarian cancer', in Berek and Hacker S Gynecologic Oncology Sixth Edition, pp. 530 - 559

Hacker NF; Friedlander ML, 2014, 'Uterine cancer', in Berek and Hacker S Gynecologic Oncology Sixth Edition, pp. 390 - 442

Friedlander M; Thigpen JT, 2014, 'Response as a measure of treatment efficacy in clinical trials: Should recist be abandoned?', in Controversies in the Management of Gynecological Cancers, pp. 91 - 100, http://dx.doi.org/10.1007/978-0-85729-910-9_9

Berek JS; Longacre T; Friedlander M, 2011, 'Ovarian, Fallopian Tube and Peritoneal Cancer', in Berek JS (ed.), Berek and Novak's Gynecology, Royal College of Obstetricians and Gynaecologists, UK, pp. 1350 - 1427

Gainford M; Friedlander M, 2011, 'Squamous Cell Carcinomas Arising From Dermoids', in Reed N; Green JA; Gershenson DM; Siddiqui N; Connor R (ed.), Rare and Uncommon Gynecological Cancers, Springer, USA, pp. 131 - 134

Hacker NF; Friedlander ML, 2010, 'Breast Disease: A Gynecologic Perspective', in Hacker &amp Moore's Essentials of Obstetrics and Gynecology, Elsevier, pp. 326 - 331, http://dx.doi.org/10.1016/b978-1-4160-5940-0.00029-1

Friedlander ML; Gershenson D; Hacker NF; Arjun G; Smitj ; Barber HM, 1997, 'Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers.', in Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers., Mercel Dekker, New York, pp. 263 - 270

Journal articles

Friedlander ML; Anderson L; Lee YC, 2025, 'Erratum to ‘Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101668] (International Journal of Gynecological Cancer (2025) 35(3), (S1048891X25001938), (10.1016/j.ijgc.2025.101668))', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2025.101953

Marth C; Moore RG; Bidziński M; Pignata S; Ayhan A; Rubio MJ; Beiner M; Hall M; Vulsteke C; Braicu EI; Sonoda K; Wu X; Frentzas S; Mattar A; Lheureux S; Chen X; Hasegawa K; Magallanes-Maciel M; Choi CH; Shalkova M; Kaen D; Wang PH; Berger R; Okpara CE; McKenzie J; Yao L; Orlowski R; Khemka V; Gilbert L; Makker V; Gomez Abuin G; Zamora LB; Alfie MS; Casarini IA; Harrison M; Ananda S; Shannon CM; Friedlander M; Meniawy T; Gao B; Baron-Hay S; Diakos C; Polterauer S; Petru E; De Bock M; Baurain JF; Van Gorp T; Altintas S; Lima JPDSN; De Freitas Junior R; Santana RO; De Melo AC; Franke FA; Zibetti Dal Molin G; Damian FB; Guedes JDC; Ellard S; Tinker A; Samouëlian V; Fortin S; Bessette P; Kolinsky M; Kumar Tyagi N; Ethier JL; MacKay H; Lim C; Pan L; An R; Zheng H; Wu Y; Zhu J; Yao S; Jia X; Huang Y; Lv W; Zhang Y; Zhou Q; Ma C; Chekerov R; Mach P; Witteler R; Marmè F; Cadoo K; Korach J; Levy T; Amnon A; Scollo P; Naglieri E; Zamagni C; Salutari V; Usami T; Nakamura K; Matsumoto K; Yamagami W; Kobayashi Y; Takano M; Kato H; Kikuchi A; Katsumata N, 2025, 'First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial', Journal of Clinical Oncology, 43, pp. 1083 - 1100, http://dx.doi.org/10.1200/JCO-24-01326

Friedlander ML; Anderson L; Lee YC, 2025, 'Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2025.101668

Phillips KA; Kotsopoulos J; Domchek SM; Terry MB; Chamberlain JA; Bassett JK; Aeilts AM; Andrulis IL; Buys SS; Cui W; Daly MB; Eisen AF; Foulkes WD; Friedlander ML; Gronwald J; Hopper JL; John EM; Karlan BY; Kim RH; Kurian AW; Lubinski J; Metcalfe K; Nathanson KL; Singer CF; Southey MC; Symecko H; Tung N; Narod SA; Milne RL; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Bodek S; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Chenevix-Trench G; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; Defazio A; Delatycki M; Dickson R; Dixon J; Edwards S; Farshid G; Fellows A; Fenton G; Field M; Flanagan J; Fong P; Forrest L; Fox S; French J; Gaff C; Gattas M; George P; Greening S; Harris M; Hart S; Harraka P; Hayward N; Hopper J; Hoskins C; Hunt C; James P; Jenkins M; Kidd A; Kirk J; Koehler J; Kollias J; Lakhani S; Lawrence M; Lee J; Li S; Lindeman G; Lippey J; Lipton L; Lobb L; Loi S; Mann G, 2025, 'Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2', Journal of Clinical Oncology, 43, pp. 422 - 431, http://dx.doi.org/10.1200/JCO.24.00176

Lee YC; Whitely A; Burling M; Anderson L; Cohen PA; Naidoo M; Richardson G; Perera S; Scott CL; Friedlander M; Brand A; McNally O; Hyde S; Bunting M; Jobling T; Zalcberg J; Rome R, 2025, 'Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2024.100052

Na R; Jordan SJ; DeFazio A; Williams M; Livingstone K; Obermair A; Friedlander M; Grant P; Webb PM, 2025, 'Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival—A prospective cohort study in Australia', International Journal of Cancer, 156, pp. 280 - 292, http://dx.doi.org/10.1002/ijc.35154

Francis KE; Simon S; Gebski V; Joly F; Ledermann JA; Penson RT; Oza AM; Korach J; Lainez N; Cecere SC; Tasca G; Gropp-Meier M; Fujiwara K; Lowe ES; Friedlander M; Pujade-Lauraine E; Lee CK, 2025, 'Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer', Gynecologic Oncology, 192, pp. 50 - 55, http://dx.doi.org/10.1016/j.ygyno.2024.11.004

Pitiyarachchi O; Friedlander M, 2025, 'Age disparities in clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with high grade serous ovarian cancer: A wake up call to improving outcomes in older patients', Journal of Geriatric Oncology, 16, http://dx.doi.org/10.1016/j.jgo.2024.102152

Gersekowski K; Defazio A; Friedlander M; Obermair A; Webb PM, 2025, 'Green tea consumption, primary treatment outcome and survival after a diagnosis of ovarian cancer', Journal of Epidemiology and Community Health, http://dx.doi.org/10.1136/jech-2024-222687

Na R; Nagle CM; Bartsch S; Ibiebele TI; Williams M; Grant P; Friedlander ML; Webb PM, 2025, 'Use of Dietary Supplements Before, During and After Treatment for Ovarian Cancer: Results from the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study', Nutrition and Cancer, 77, pp. 200 - 209, http://dx.doi.org/10.1080/01635581.2024.2408775

Campbell R; Jeon M; Friedlander M; King MT; Obermair A; Bilic S; Brand A; Butow P; Codde J; Gebski V; Goh JC; Ives A; Lawson W; McNally O; Meniawy T; Mileshkin LR; Morton RL; Webb PM; Yates P; Cohen PA, 2025, '“The telehealth means I get distance from the hospital so I don’t feel so much like a patient”: A qualitative sub-study examining the acceptability of nurse-led follow-up for ovarian cancer via telehealth using the MOST-S26 to structure consultations.', Journal of Clinical Oncology, 43, pp. 12099 - 12099, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.12099

Petousis S; Kahramanoglu I; Appenzeller-Herzog C; Kacperczyk-Bartnik J; Angeles MA; Bilir E; Caruso G; Friedlander M; Margioula-Siarkou C; Sotiriadis A; Heinzelmann-Schwarz V; Zwimpfer TA, 2025, 'Efficacy And Safety Of PARP Inhibitor Maintenance In Platinum-Sensitive Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review And Meta-Analysis', International Journal of Gynecological Cancer, 35, pp. 100336 - 100336, http://dx.doi.org/10.1016/j.ijgc.2024.100336

Nahm SH; Kiely BE; O'Connell RL; Lee YC; Davis A; Avall-Lundqvist E; Berek JS; Berton D; Donnellan P; Hilpert F; Joly F; Lanceley A; Ledermann JA; Okamoto A; Oza A; Pignata S; Sehouli J; King MT; Friedlander M; Stockler MR; Roncolato FT; GCIG Symptom Benefit Group , 2025, 'Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.', Int J Gynecol Cancer, 35, pp. 100030, http://dx.doi.org/10.1016/j.ijgc.2024.100030

Haggstrom L; Lee YC; Scott C; Harter P; Woelber L; Ledermann J; Gourley C; McNeish IA; Amant F; Ray-Coquard I; Leary A; Oza AM; Tinker A; González Martin A; Cecere SC; Pignata S; Colombo N; Yoshida H; Marth C; Rosengarten O; Moore KN; Gómez-García EM; Tan D; Friedlander ML, 2024, 'How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes', International Journal of Gynecological Cancer, 34, pp. 1932 - 1939, http://dx.doi.org/10.1136/ijgc-2024-005976

Ramachandran D; Tyrer JP; Kommoss S; DeFazio A; Riggan MJ; Webb PM; Fasching PA; Lambrechts D; García MJ; Rodríguez-Antona C; Goodman MT; Modugno F; Moysich KB; Karlan BY; Lester J; Kjaer SK; Jensen A; Høgdall E; Goode EL; Cliby WA; Kumar A; Wang C; Cunningham JM; Winham SJ; Monteiro AN; Schildkraut JM; Cramer DW; Terry KL; Titus L; Bjorge L; Thomsen LCV; Pejovic T; Høgdall CK; McNeish IA; May T; Huntsman DG; Pfisterer J; Canzler U; Park-Simon TW; Schröder W; Belau A; Hanker L; Harter P; Sehouli J; Kimmig R; de Gregorio N; Schmalfeldt B; Baumann K; Hilpert F; Burges A; Winterhoff B; Schürmann P; Speith LM; Hillemanns P; Berchuck A; Johnatty SE; Ramus SJ; Chenevix-Trench G; Pharoah PDP; Dörk T; Heitz F; Bowtell D; Fereday S; Traficante N; Hung J; Friedlander M; Obermair A; Grant P; Beesley V; Blomfield P; Brand A; Davis A; Leung Y; Nicklin J; Quinn M; Livingstone K; O’Neill H; Williams M, 2024, 'Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease', Npj Genomic Medicine, 9, http://dx.doi.org/10.1038/s41525-024-00395-y

Tjokrowidjaja A; Kok PS; Antill YC; Scott CL; Mileshkin LR; Friedlander ML; Lee CK, 2024, 'Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas—a meta-analysis', Jnci Cancer Spectrum, 8, http://dx.doi.org/10.1093/jncics/pkae101

Lefkovits YR; Heriot N; Sporik A; Perera S; Friedlander M; Dixon C; Cohen PA; Lee YC; Hyde S; Richardson G; Webb P; Rome R; King M; Zalcberg J; Schofield P, 2024, 'Incorporating patient-reported outcome measures (PROMs) into a clinical quality registry (CQR) for ovarian cancer: considerations and challenges', BMC Health Services Research, 24, http://dx.doi.org/10.1186/s12913-024-11042-8

Burdett NL; Willis MO; Pandey A; Twomey L; Alaei S; Bowtell D; Chenevix-Trench G; Green A; Webb P; DeFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; Malt M; Chiew YE; Stenlake A; Sullivan H; Mellon A; Robertson R; Bergh TV; Jones M; Mackenzie P; Maidens J; Nattress K; White J; Jayde V; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Ball C; Young C; Brooks J; Mileshkin L; Au-Yeung G; Phillips K; Rischin D; Delahunty R; Christie E; Garsed D; Fox S; Johnson D; Lade S; Loughrey M; O’Callaghan N; Murray W; Purdie D; Whiteman D; Proietto A; Braye S; Otton G; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Beale P; Beith J; Carter J; Dalrymple C; Houghton R; Russell P; Davy M; Oehler MK; Hall C; Dodd T; Blomfield P, 2024, 'Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-50137-y

Ross TL; Na R; Au-Yeung G; DeFazio A; Friedlander M; Sivakumaran T; Livingstone K; Nagle CM; O'Neill H; Williams M; Webb PM; Beesley VL, 2024, 'Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?', Gynecologic Oncology, 190, pp. 53 - 61, http://dx.doi.org/10.1016/j.ygyno.2024.07.684

Ray-Coquard I; Casali PG; Croce S; Fennessy FM; Fischerova D; Jones R; Sanfilippo R; Zapardiel I; Amant F; Blay JY; Martin-Broto J; Casado A; Chiang S; Dei Tos AP; Haas R; Hensley ML; Hohenberger P; Kim JW; Kim SI; Meydanli MM; Pautier P; Abdul Razak AR; Sehouli J; Van Houdt W; Planchamp F; Friedlander M, 2024, 'ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas', International Journal of Gynecological Cancer, 34, pp. 1499 - 1521, http://dx.doi.org/10.1136/ijgc-2024-005823

Zwimpfer TA; Ewald H; Bilir E; Jayawardana M; Appenzeller-Herzog C; Bizzarri N; Razumova Z; Kacperczyk-Bartnik J; Heinzelmann-Schwarz V; Friedlander M; Bowtell DDL; Garsed DW, 2024, 'Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma', Cochrane Database of Systematic Reviews, 2024, http://dx.doi.org/10.1002/14651858.CD015896

McDonald JA; Liao Y; Knight JA; John EM; Kurian AW; Daly M; Buys SS; Huang Y; Frost CJ; Andrulis IL; Colonna SV; Friedlander ML; Hopper JL; Chung WK; Genkinger JM; Macinnis RJ; Terry MB, 2024, 'Pregnancy-Related Factors and Breast Cancer Risk for Women Across a Range of Familial Risk', JAMA Network Open, 7, pp. e2427441, http://dx.doi.org/10.1001/jamanetworkopen.2024.27441

Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy', JAMA Network Open, 7, pp. e2424139, http://dx.doi.org/10.1001/jamanetworkopen.2024.24139

Pitiyarachchi O; Ansell PJ; Coleman RL; Dinh MH; Holman L; Leath CA; Werner T; DiSilvestro P; Morgan M; Tew W; Lee C; Cunningham M; Newton M; Edraki B; Lim P; Barlin J; Spirtos NM; Tewari KS; Edelson M; Reid T; Carlson J; Friedlander M, 2024, 'Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over', Gynecologic Oncology, 187, pp. 221 - 226, http://dx.doi.org/10.1016/j.ygyno.2024.05.021

Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M, 2024, 'Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer', Gynecologic Oncology, 185, pp. 128 - 137, http://dx.doi.org/10.1016/j.ygyno.2024.02.025

Li T; Timmins HC; Mahfouz FM; Mizrahi D; Horvath L; Harrison ML; Grimison PS; Friedlander M; Marx GM; Boyle FM; Wyld D; Henderson R; King T; Baron-Hay SE; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Identifying optimized assessment of nerve damage during chemotherapy.', Journal of Clinical Oncology, 42, pp. 12016 - 12016, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12016

Naidoo M; Scott CL; McNally O; Rome R; Perera S; Lee YC; Whitely A; Burling M; Anderson L; Cohen P; Richardson GE; Friedlander M; Brand A; Hyde S; Bunting M; Jobling T; Zalcberg JR, 2024, 'Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR).', Journal of Clinical Oncology, 42, pp. e17554 - e17554, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e17554

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin L; Ananda S; Shannon C; Friedlander M; Warton K; Ford CE, 2024, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial', Translational Oncology, 43, http://dx.doi.org/10.1016/j.tranon.2024.101914

Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.', Support Care Cancer, 32, pp. 292, http://dx.doi.org/10.1007/s00520-024-08460-z

Ganz PA; Bandos H; Španić T; Friedman S; Müller V; Kuemmel S; Delaloge S; Brain E; Toi M; Yamauchi H; De Dueñas EM; Armstrong A; Im SA; Song CG; Zheng H; Sarosiek T; Sharma P; Geng C; Fu P; Rhiem K; Frauchiger-Heuer H; Wimberger P; T'Kint De Roodenbeke D; Liao N; Goodwin A; Chakiba-Brugère C; Friedlander M; Lee KS; Giacchetti S; Takano T; Henao-Carrasco F; Virani S; Valdes-Albini F; Domchek SM; Bane C; McCarron EC; Mita M; Rossi G; Rastogi P; Fielding A; Gelber RD; Scheepers ED; Cameron D; Garber J; Geyer CE; Tutt ANJ, 2024, 'Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer', Journal of Clinical Oncology, 42, pp. 1288 - 1300, http://dx.doi.org/10.1200/JCO.23.01214

Tjokrowidjaja A; Friedlander ML; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Lord SJ; Scott CL; Goble S; York W; Lee CK; Khoon Lee C; You B; Paoletti X; Glasspool R; Friedlander M; Mirza M; Antill Y; Mileshkin L; Ethier JL; Bookman M; Gourley C, 2024, 'Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor', Journal of Clinical Oncology, 42, pp. 1301 - 1310, http://dx.doi.org/10.1200/JCO.23.01182

Yeung N; Li T; Lin HM; Timmins HC; Goldstein D; Harrison M; Friedlander M; Mahon KL; Giles C; Meikle PJ; Park SB; Horvath LG, 2024, 'Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00690

Diéras V; Han HS; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Loirat D; Ratajczak C; Adamu H; Girardi V; Arun BK, 2024, 'Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial', European Journal of Cancer, 200, http://dx.doi.org/10.1016/j.ejca.2024.113580

Zebic DS; Tjokrowidjaja A; Francis KE; Friedlander M; Gebski V; Lortholary A; Joly F; Hasenburg A; Mirza M; Denison U; Cecere SC; Ferrero A; Pujade-Lauraine E; Lee CK, 2024, 'Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer', British Journal of Cancer, 130, pp. 425 - 433, http://dx.doi.org/10.1038/s41416-023-02528-z

Woodford R; Zhou D; Kok PS; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK, 2024, 'Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00296

Back to profile page